04:23 PM EDT, 08/04/2025 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) reported fiscal Q2 non-GAAP net income late Monday of $4.52 per diluted share, swinging from a loss of $12.83 a year earlier.

Analysts polled by FactSet expected earnings of $4.27.

Revenue in the three months ended June 30 rose to $2.96 billion from $2.65 billion a year earlier.

Analysts expected $2.91 billion.

The company reiterated 2025 revenue guidance of $11.85 billion to $12 billion.

Analysts project $11.93 billion.